FDA Recommends Precautionary Language On Neuropsychiatric Events For Tamiflu
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency’s Pediatric Advisory Committee will also evaluate updated adverse event data from the 2006-2007 flu season for GSK’s Relenza.
You may also be interested in...
Influenza Itself Could Contribute To Psychiatric Events Connected With Tamiflu
Roche's position, which they hope to include in labeling, follows comments voiced by some members during a Nov. 27 Pediatric Advisory Committee meeting.
Influenza Itself Could Contribute To Psychiatric Events Connected With Tamiflu
Roche's position, which they hope to include in labeling, follows comments voiced by some members during a Nov. 27 Pediatric Advisory Committee meeting.
Tamiflu U.S. Labeling Adopts Japanese Warnings
Neuropsychiatric adverse event reports for Roche's antiviral jump in most recent review, prompting FDA staff to suggest a labeling change.